abstract |
Disclosed are methods of in situ genomic modification of cells (e.g., stem cells, tissue stem cells, muscle stem cells, Sca-1* mesenchymal progenitor cells in skeletal muscle, CD140a* dermal mesenchymal cells) using sequence-targeting nucleases delivered via a virus (e.g., an AAV). |